1.1 Introduction
Artificial Intelligence in drug discovery refers to the application of advanced computational algorithms, machine learning models, and data analytics techniques to identify drug targets, design therapeutic compounds, predict drug interactions, and optimize clinical outcomes. It is transforming pharmaceutical research by enabling faster hypothesis generation, virtual screening of millions of molecules, and predictive modeling of drug safety and efficacy. Unlike traditional drug discovery methods that rely heavily on laboratory experimentation and prolonged clinical trials, AI-driven approaches are improving efficiency by leveraging biomedical big data, genomics, proteomics, and real-world patient records to guide decision-making processes (Makurvet, 2021; Paul et al., 2021).
This chapter will address the background information that motivated this study, the challenges that prompted it, its aim, and its objectives as a preface to subsequent sections of the study. Additional factors include the study's significance, scope, limitations, research questions and hypotheses, and the definition of technical terms.
1.2 Background of Study
Globally, the integration of AI into pharmaceutical innovation is reshaping the structure of drug development pipelines. AI systems are supporting target identification, biomarker discovery, drug repurposing, and precision medicine initiatives. Pharmaceutical companies and research institutions are deploying deep learning and neural network models to reduce research timelines and development costs, which historically span over a decade with significant financial risk. Studies indicate that AI-enabled drug discovery is improving success rates in preclinical trials and facilitating the design of personalized therapeutics tailored to specific genetic and environmental profiles (Zhavoronkov et al., 2020).
Drug discovery traditionally involves target identification, compound screening, preclinical testing, and multi-phase clinical trials, a process that often spans over ten to fifteen years with high financial risk and low success rates. According to Makurvet (2021), AI is transforming this paradigm by applying machine learning algorithms and computational models to accelerate drug design, predict molecular behavior, and optimize therapeutic outcomes. He asserted that AI-driven systems are reducing experimental bottlenecks by enabling virtual screening of vast chemical libraries within significantly shorter timeframes.
Paul et al. (2021) reported that AI technologies are improving biomarker discovery, disease modeling, and drug repurposing by leveraging biomedical big data and real-world clinical evidence. They affirmed that deep learning models are improving predictive accuracy in toxicity profiling and drug efficacy, thereby reducing late-stage clinical trial failures. Similarly, Zhavoronkov et al. (2020) contended that AI is redefining the economics of drug discovery by lowering development costs and enabling the creation of novel molecular entities through generative algorithms.
The application of AI in drug discovery is particularly significant in the context of developing countries where healthcare systems face resource constraints and high disease burdens. In Africa, and Nigeria specifically, endemic diseases such as malaria, tuberculosis, and neglected tropical diseases continue to exert pressure on public health systems. According to Adebayo et al. (2022), pharmaceutical innovation capacity in Nigeria remains limited due to inadequate research infrastructure, low investment in biomedical research, and reliance on imported drugs. The authors stated that local drug development efforts are often constrained by insufficient laboratory technologies and fragmented clinical datasets, which slow therapeutic innovation.
Data availability and quality constitute another critical dimension in AI-enabled drug discovery. AI systems rely heavily on large, structured, and diverse datasets to train predictive models. Chibuzor et al. (2023) asserted that Africa faces significant genomic and biomedical data gaps, limiting the contextual relevance of many AI drug discovery tools trained on Western population datasets. They contended that the lack of localized data reduces algorithmic accuracy when applied to African populations due to genetic diversity, environmental differences, and unique disease epidemiology. This data disparity underscores the need for indigenous AI platforms capable of generating and utilizing context-specific pharmaceutical datasets.
Nigeria's digital health ecosystem is gradually evolving to support AI integration. The expansion of electronic health records, telemedicine platforms, and health data analytics infrastructure is creating foundational datasets required for AI modeling. The World Health Organization (2023) affirmed that digital health transformation is enabling countries to harness AI for clinical decision support, drug safety monitoring, and therapeutic innovation. However, the organization reported that regulatory readiness, data governance frameworks, and workforce capacity remain critical determinants of successful AI adoption in healthcare systems. This study is set against the backdrop of growing interest in leveraging artificial intelligence to strengthen pharmaceutical research capacity in Nigeria.
1.3 Statement of Problems
Investigation revealed that drug development in Nigeria continues to rely heavily on conventional laboratory methods that are time intensive, capital demanding, and often constrained by inadequate research infrastructure. Many pharmaceutical firms and research institutions face challenges such as fragmented biomedical data, limited computational facilities, and insufficient collaboration between AI technologists and drug researchers (Adebayo et al., 2022).
Additionally, Most AI pharmaceutical tools are trained on Western population data, which is not fully representative of African genomic diversity, environmental exposure, and disease epidemiology. Consequently, without indigenous platforms and datasets, the promise of AI-driven drug discovery is remaining underutilized in addressing Nigeria's unique healthcare challenges (Chibuzor et al., 2023).
Furthermore, policy and investment gaps are limiting the scalability of AI in Nigeria's pharmaceutical sector. Government funding for AI-health research is relatively low, and private sector investment in computational drug discovery is still emerging. Universities and research institutes are also lacking interdisciplinary programs that integrate pharmaceutical sciences with artificial intelligence engineering. It is against this backdrop that this study seeks to examine the integration of AI in drug discovery in Nigeria through a case study of the Pharmarun AI Drug Matching Platform.
1.4 Aim and Objectives of Study
The aim of this study is to evaluate the role and impact of AI integration in drug discovery in Nigeria, using the Pharmarun AI Drug Matching Platform as a case study. In achieving this aim, the following specific objectives were laid out as follows:
- To assess the effectiveness of Pharmarun in improving drug matching and therapeutic optimization.
- To identify the challenges and barriers to AI adoption in drug discovery in Nigeria.
- To evaluate the impact of AI-driven drug discovery platforms on research efficiency and clinical decision-making.
- To provide recommendations for improving the integration and adoption of AI in Nigeria's pharmaceutical sector.
1.5 Research Questions
The study came up with research questions so as to be able to ascertain the above stated objectives. The specific research questions for the study are stated below as follows:
- How effective is the Pharmarun AI Drug Matching Platform in improving drug matching and therapeutic outcomes?
- What are the major challenges hindering the adoption of AI in drug discovery in Nigeria?
- How does AI integration influence the efficiency of drug discovery and clinical decision-making in Nigeria?
- What strategies can be implemented to enhance the adoption and integration of AI in Nigeria's pharmaceutical research sector?
1.6 Research Hypothesis
In order to pursue the objective of this study, the following generalized statements have been designed to guide and aids in obtaining the result for the experiment to be conducted. For this work, the null hypothesis will be represented with H0 while the alternative hypothesis will be represented with hypothesis H1.
- H0: The integration of AI in drug discovery, using the Pharmarun AI Drug Matching Platform, does not significantly improve the efficiency and effectiveness of pharmaceutical research in Nigeria.
- H1: The integration of AI in drug discovery, using the Pharmarun AI Drug Matching Platform, significantly improves the efficiency and effectiveness of pharmaceutical research in Nigeria.
1.7 Significance of Study
It is believed that at the completion of the study, the findings will show how the integration of AI platforms like Pharmarun will foster innovation ecosystems where technology and medicine converge to create sustainable solutions for Nigeria's healthcare challenges. Also, this research will inform decision-making regarding investments in AI technologies, the development of regulatory frameworks, and the creation of policies to promote digital health innovation.
Furthermore, the research will inform strategies for creating supportive frameworks for AI adoption and data governance in healthcare. In addition, the findings will demonstrate how AI integration will improve access to personalized therapies and treatment effectiveness.
Lastly, the study will contribute to the literature on AI in drug discovery, providing a case study for future scholarly work.
1.8 Scope of Study
The study focuses on the integration of AI in drug discovery within Nigeria, specifically through the Pharmarun AI Drug Matching Platform.
The study is geographically centered on Lagos State, where Pharmarun has its primary operations, and targets pharmaceutical research institutions, AI developers, and clinical practitioners involved with the platform.
1.9 Limitations of the Study
A study of this nature is bound to experience certain problems as such the constraints imposed on the research include:
- The study was limited by insufficient data availability from research institutions and healthcare facilities.
- There was delay from respondents in completing questionnaires and interviews, which slowed the research process.
- Financial constraints restricted the scope of fieldwork and sample size, while time constraints impacted the depth of data analysis and literature review.
1.10 Definition of Terms
Artificial Intelligence (AI):
According to Makurvet (2021), AI is the application of computer systems and algorithms that can perform tasks requiring human intelligence, such as pattern recognition, prediction, and decision-making in complex systems.
Drug Discovery:
Paul et al. (2021) defined drug discovery as the systematic process of identifying new candidate medications, testing their efficacy, and developing them into therapeutically effective drugs.
Pharmarun AI Drug Matching Platform:
Olawale and Eze (2024) described Pharmarun as an indigenous AI-driven platform in Nigeria that matches patients with optimal drug therapies by analyzing medical histories, symptoms, and pharmacological databases to support personalized treatment and drug discovery research.
Clinical Decision Support:
According to World Health Organization (2023), clinical decision support refers to tools and systems that provide healthcare professionals with knowledge and patient-specific information, intelligently filtered or presented at appropriate times, to enhance patient care decisions.
Digital Health:
Chibuzor et al. (2023) stated that digital health encompasses the use of information and communication technologies, including AI, to improve healthcare delivery, research, and patient outcomes.
…